Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Oct 4;25(10):2241-2243.
doi: 10.1016/j.ymthe.2017.09.005. Epub 2017 Sep 21.

A Possible Cure for Refractory DLBCL: CARs Are Headed in the Right Direction

Julio C Chavez  1 , Frederick L Locke  2
Affiliations
Comment

A Possible Cure for Refractory DLBCL: CARs Are Headed in the Right Direction

Julio C Chavez et al. Mol Ther. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Kochenderfer J.N., Somerville R.P.T., Lu T., Yang J.C., Sherry R.M., Feldman S.A., McIntyre L., Bot A., Rossi J., Lam N., Rosenberg S.A. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther. 2017;25:2245–2253. this issue. - PMC - PubMed
    1. Coiffier B., Thieblemont C., Van Den Neste E., Lepeu G., Plantier I., Castaigne S., Lefort S., Marit G., Macro M., Sebban C. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–2045. - PMC - PubMed
    1. Crump M., Neelapu S.S., Farooq U., Van Den Neste E., Kuruvilla J., Ahmed M.A., Link B.K., Hay A.E., Cerhan J.R., Zhu L. Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. J Clin Oncol. 2016;34(15_suppl) 7516–7516. - PMC - PubMed
    1. Kochenderfer J.N., Wilson W.H., Janik J.E., Dudley M.E., Stetler-Stevenson M., Feldman S.A., Maric I., Raffeld M., Nathan D.A., Lanier B.J. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116:4099–4102. - PMC - PubMed
    1. Turtle C.J., Hanafi L.A., Berger C., Hudecek M., Pender B., Robinson E., Hawkins R., Chaney C., Cherian S., Chen X. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med. 2016;8:355ra116. - PMC - PubMed